# US 2024/0277793 A1 · Oncolytic viruses for modified mhc expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0277793 A1
- Document ID: US20240277793A1
- Status: Published application
- Kind: A1
- Application number: 18/606,128
- Filed: 2024-03-15
- Published: 2024-08-22
- Earliest claimed: 2021-04-30
- Assignees: KaliVir Immunotherapeutics, Inc.
- Applicants: KaliVir Immunotherapeutics, Inc.
- Inventors: Stephen Howard THORNE; Mingrui ZHANG
- Web page: https://patentgrep.com/patent/US20240277793A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C07K 14/065: Poxviridae, e.g. avipoxvirus
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

## Claims

### Claim 1

A composition, wherein the composition comprises:
an oncolytic virus, wherein the oncolytic virus comprises a genome modification, wherein the genome modification comprises an insertion of an exogenous nucleic acid encoding for a modified CXCR4,
wherein the modified CXCR4 comprises an amino acid substitution at a position corresponding to Y157 of SEQ ID NO: 20.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amino acid substitution at the position corresponding to Y157 of SEQ ID NO: 20 is Y157A.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the modified CXCR4 comprises an amino acid sequence of SEQ ID NO: 18.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the oncolytic virus comprises a poxvirus, an adeno associated virus, an adenovirus, Newcastle disease virus (NDV), Reovirus (RV), mengovirus, Myxoma virus (MYXV), Measles virus (MV), Herpes Simplex virus (HSV), Vaccinia virus (VV), Vesicular Stomatitis virus (VSV), and Polio virus (PV).

### Claim 5 (depends on 4)

The composition of claim 4, wherein the poxvirus comprises a betaentomopoxvirus, a yatapoxvirus, a cervidpoxvirus, a gammaentomopoxvirus, a leporipoxvirus, a suipoxvirus, a molluscipoxvirus, a crocodylidpoxvirus, an alphaentomopoxvirus, a capripoxvirus, an avipoxvirus, or a parapoxvirus.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the oncolytic virus is a vaccinia virus.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the vaccinia virus is a Western Reserve strain Vaccinia virus (ATCC VR-1354), a Copenhagen strain, an IHD strain, a Wyeth strain (ATCC VR-325), a NYCBOH strain, a Tian Tan strain, a Lister strain, an Ankara strain (ATCC VR-1508 or ATTC VR1566), a USSR strain, or an ACAM2000 strain.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the genome modification reduces an immune response targeting a virus-infected tumor cell and increases an immune response targeting cells surrounding the virus-infected tumor cell.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the genome modification comprises mutation or a complete or a partial deletion of a viral gene comprising at least one of: A52R, B15R, K7R, A46R, N1L, E3L, K1L, M2L, C16, N2R, B8R, B18R, or VH1 of a vaccinia virus or a functional domain or fragment or variant thereof, or any combinations thereof.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the genome modification comprises a mutation or a deletion or a partial deletion of an A52R gene.

### Claim 11 (depends on 10)

The composition of claim 10, further comprising a deletion of a thymidine kinase gene.

### Claim 12 (depends on 1)

The composition of claim 1, further comprising a deletion of a thymidine kinase gene.

### Claim 13 (depends on 1)

A method of treating cancer, comprising administering to a subject having cancer the oncolytic virus of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the administration is intratumoral, intravenous, parenteral, intradermal, intramuscular, transdermal, rectal, intraurethral, intravaginal, intranasal, intrathecal, intraperitoneal, intradental, subcutaneous, percutaneous, intratracheal, intraarterial, intravesical, inhalation, or oral.

### Claim 15 (depends on 13)

The method of claim 13, wherein the administration is intratumoral.

### Claim 16 (depends on 13)

The method of claim 13, wherein the administration is intravenous.

### Claim 17 (depends on 13)

The method of claim 13, wherein the cancer is a solid cancer or a blood cancer.
